Clinical Trial Update: SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating S-adenosyl-L-methionine (SAMe) for prevention of liver cancer in MASLD-related cirrhosis; recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis
• Metabolic Dysfunction-associated Steatotic Liver Disease

Drugs mentioned

• SAMe (S-adenosyl-L-methionine)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Phase 2 | Status: NOT_YET_RECRUITING